Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-ZRCHP in previously untreated non-GCB DLBCL
ChiCTR2600119915Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, zanubrutinib, rituximab, cyclophosphamide, doxorubicin and 1 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 2-year progression-free survival (2-year PFS). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotinzanubrutinibrituximabcyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600119915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119915.